Abstract 1146P
Background
Oral Mucosal Melanoma (OMM) is the main subtype of melanoma in Chinese population. DTIC single-agent chemotherapy of OMM has a poor efficacy. Persistent angiogenesis is an important characteristic of OMM, Rh-endostatin (Endostar) can inhibit the angiogenesis of tumor and has a synergistic effect on chemotherapy.
Methods
Medical information of 68 patients diagnosed with Oral Mucosal Melanoma without clinical cervical lymph node metastasis in the department of Oral and Maxillofacial-Head and neck Oncology, Shanghai Ninth People's hospital, Shanghai Jiao Tong University School of Medicine from 2012 to 2017 were collected. The patients were divided into two groups, group A was treated with chemotherapy containing DTIC combined with interferon therapy, group B was added Endostar (30 mg/day, continuous infusion, day 1-7) at the time of chemotherapy.
Results
Baseline demographics and disease characteristics were generally balanced between the two treatment groups. The median age at diagnosis was 55 years old. Male patients compose 53% (36 out of 68 patients) of patients. At the time of treatment, 19 (28%) patients were diagnosed with T stage IV. The locations of OMM were commonly gingiva and palate, occasionally lip, tongue and buccal. The median OS and median DFS in group A is 37 (95% CI 32.41-41.59) months and 24 (95% CI 8.79-39.25) months respectively. The median OS and median DFS in group B is not reached. Patients treated with Endostar were less likely to develop local recurrence, regional recurrence and metastasis. No severe adverse event related to Endostar was reported.
Conclusions
Endostar combined with chemotherapy and interferon can significantly reduce the recurrence risk and improve the long-term survival rate in OMM without clinical cervical lymph node metastasis. Anti-tumor neovascularization therapy can be used as an effective adjuvant therapy strategy for OMM. Adverse reactions caused by Endostar have rarely been reported. Therefore, Endostar is more suitable for the combined treatment of OMM without clinical cervical lymph node metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People' s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.